Dylan Burger profile picture

Contact Information

Dylan Burger, PhD
613-562-5800 x 8241

2513-451 Smyth Rd.
Ottawa, ON
K1H 7N9

ORCID logo https://orcid.org/0000-0003-3951-2911

Dylan Burger

Senior Scientist, Chronic Disease Program
Ottawa Hospital Research Institute
Associate Professor, Department of Cellular and Molecular Medicine
University of Ottawa

Research Interests

Brief Biography

Dylan Burger, PhD is a Senior Scientist at the Ottawa Hospital Research Institute (Chronic Disease Program, Kidney Research Centre) and Associate Professor in the Departments of Cellular and Molecular Medicine and Medicine at the University of Ottawa. He received his PhD in Pharmacology and Toxicology from the University of Western Ontario in 2008 under the supervision of Dr. Qingping Feng. From 2009-2012 his postdoctoral training in the laboratory of Dr. Rhian Touyz focused on understanding mechanisms of microparticle signaling, oxidative stress and intercellular communication in hypertension and vascular disease. He completed a second postdoctoral fellowship working with Dr. Kevin Burns in the areas of regenerative medicine for acute kidney injury. His research program is funded through the Canadian Institutes of Health Research, the Kidney Foundation of Canada, and the Canada Foundation for Innovation. He has received several awards including a KRESCENT New Investigator Award (2013), the Canadian Society of Nephrology/Amgen New Investigator Lectureship Award (2015), the Ottawa Department of Medicine PhD Scientist Award (2018), and an Ontario Early Researcher Award (2018). He is an Associate Editor for the European Heart Journal, is the current Chair of Communications for the International Society of Hypertension and is a member of The Lancet Commission on Hypertension. Dr. Burger’s laboratory aims to understand to cellular mechanisms governing extracellular vesicle formation and signaling in vascular and renal disease. 

Selected Publications

1. Burger D+*, Turner M, Xiao F, Munkonda M, Akbari S, Burns KD* (2017) “High glucose increases the formation and pro-oxidative activity of endothelial microparticles”. Diabetologia (Epub ahead of print).

2. Akbari S, Abou-Arkoub R, Sun S, Hiremath S, Reunov A, McCormick B*, Ruzicka M*, Burger D*+ (2017) “Microparticle formation in peritoneal dialysis: a proof of concept study”. Can J Kid Health Dis 4: 1-8.

3. Lytvyn Y, Xiao F, Perkins BA, Kennedy CR, Reich HN, Scholey JW, Cherney DZ, Burger D+ (2017) “Assessment of Urinary Microparticles in Normotensive Patients with Type 1 Diabetes”. Diabetologia, 60(3) 581-584.

4. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C, Giminez-Roqueplo A, Hering D, López-Jaramillo P, Martinez F, Perkovic V, Rietzschel ER, Schillaci G, Schutte AE, Scuteri A, Sharman JE, Wachtell K, Wang JG (2016) “A call to action and a life-course strategy to address the global burden of raised blood pressure on current and future generations: The Lancet Commission on Hypertension”. Lancet 26;388(10060):2665-2712.

5. Burger D, Thibodeau JF, Holterman CE, Burns KD, Touyz RM, Kennedy CRJ (2014) “Urinary podocyte microparticles identify pre-albuminuric diabetic glomerular injury”. J Am Soc Nephrol 25(7) 1401-1407

6. Burger D+, Schock S, Thompson CS, Montezano AC, Hakim AM, Touyz RM (2013) “Microparticles: Biomarkers and Beyond”. Clin Sci 124(7) 423-441

Diseases, conditions and populations of interest

Research and clinical approaches